Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to Post Q1 2023 Earnings of ($1.41) Per Share, William Blair Forecasts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) – Equities research analysts at William Blair lowered their Q1 2023 earnings per share estimates for Sarepta Therapeutics in a research note issued to investors on Wednesday, March 1st. William Blair analyst T. Lugo now anticipates that the biotechnology company will earn ($1.41) per share for the quarter, down from their prior forecast of ($1.24). The consensus estimate for Sarepta Therapeutics’ current full-year earnings is ($4.37) per share. William Blair also issued estimates for Sarepta Therapeutics’ Q2 2023 earnings at ($1.26) EPS, Q3 2023 earnings at ($0.95) EPS, Q4 2023 earnings at ($0.56) EPS and FY2023 earnings at ($4.18) EPS.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.04. The company had revenue of $258.43 million for the quarter, compared to the consensus estimate of $250.51 million. Sarepta Therapeutics had a negative return on equity of 117.29% and a negative net margin of 75.40%. The firm’s revenue was up 28.3% compared to the same quarter last year. During the same period last year, the business posted ($1.42) earnings per share.

Several other analysts have also issued reports on SRPT. Cantor Fitzgerald increased their price target on shares of Sarepta Therapeutics from $150.00 to $174.00 in a research report on Tuesday, December 13th. BTIG Research raised their price target on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, December 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Sarepta Therapeutics from $153.00 to $206.00 and gave the company an “overweight” rating in a report on Friday. Robert W. Baird raised their price target on shares of Sarepta Therapeutics from $152.00 to $202.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Finally, Morgan Stanley raised shares of Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $141.00 to $187.00 in a research report on Wednesday, March 1st. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $173.60.

Sarepta Therapeutics Stock Up 1.7 %

Shares of SRPT stock opened at $155.61 on Monday. The company has a debt-to-equity ratio of 4.01, a quick ratio of 3.99 and a current ratio of 4.13. The firm’s 50-day moving average is $125.50 and its 200-day moving average is $117.79. The stock has a market cap of $13.69 billion, a price-to-earnings ratio of -19.38 and a beta of 0.97. Sarepta Therapeutics has a 52-week low of $61.28 and a 52-week high of $157.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FourThought Financial LLC grew its holdings in Sarepta Therapeutics by 43.5% in the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the period. Hanseatic Management Services Inc. bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $35,000. Armstrong Advisory Group Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $39,000. Cullen Frost Bankers Inc. bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $44,000. Finally, C M Bidwell & Associates Ltd. grew its stake in Sarepta Therapeutics by 1,966.7% during the second quarter. C M Bidwell & Associates Ltd. now owns 620 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 590 shares in the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.